with superimposed preeclampsia ("cHTN+preSF") and those with preeclampsia with severe features ("preSF"). We abstracted clinical information, including maternal BMI and medication administration data from the electronic medical record system. We used Student's t-test and Chi-squared test to examine differences between the groups. We performed a two-way analysis of variance to examine the effect of maternal severe hypertension (cHTN+preSF vs preSF) and obesity (BMI 30) on the total amount of IV labetalol required during the antepartum admission. RESULTS: We identified 209 patients treated with IV labetalol, including 124 with preSF and 85 with cHTN+preSF. The average amount of labetalol required was 44.5mg for the preSF group and 72.0mg for the cHTN+preSF group (p<0.01). Mean BMI at delivery was 37.7 for preSF and 40.2 for cHTN+preSF(p¼0.04). Using a twoway analysis of variance, we modeled the total administration of IV labetalol as a function of maternal hypertension type and BMI:
Total IV labetalol (mg) ¼ 24 + 27 (if BMI 30) + 0 (if preSF) + 27 (if cHTN+preSF)
The findings were unchanged after controlling for maternal age, gravidity, and other antihypertensive medications used (Table 1) . CONCLUSION: We demonstrate that chronic hypertension and maternal obesity are independent factors that directly increase the total amount of IV labetalol required to control severe hypertension in preeclampsia. We additionally offer a simple tool for clinicians to anticipate dosing of IV labetalol in acute management of severe hypertension.
518 The risk of pregnancy-associated hypertension in pregnant women with nonalcoholic fatty liver disease OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) is a risk factor for cardiovascular diseases in later life. Although the biologic mechanism is not well understood, it likely involves metabolic factors, inflammatory reactions, and endothelial dysfunction, all of which are known pathophysiologic factors in the development of pregnancy-associated HTN, including preeclampsia. However, the risk of pregnancy-associated HTN in pregnant women with NAFLD has not been well established. This study examines the risk of pregnancy-associated HTN in pregnant women with NAFLD. STUDY DESIGN: This is a secondary analysis of a large prospective cohort study of healthy Korean women with a singleton pregnancy designed to examine the risk of gestational diabetes in women with NAFLD. Liver ultrasound was performed in all cases at 10-14 weeks of gestation and the degree of hepatic steatosis classified as Grade 0-3. At the time of liver ultrasound, maternal blood was taken and measured for selenoprotein P, a hepatokine that has been independently associated with NAFLD and cardiovascular disease. Pregnancy-associated HTN was defined as the development of gestational hypertension, preeclampsia, or eclampsia. RESULTS: Among 877 enrolled subjects, the risk of pregnancyassociated HTN increased significantly in patients with NAFLD (Fig 1) . Grade 2-3 steatosis at 10-14 weeks was a significant risk factor for the development of pregnancy-associated HTN, even after adjustment for metabolic risk factors (BMI, fasting glucose). The concentration of selenoprotein P was significantly higher in women with NAFLD vs those without NAFLD at 10-14 weeks (p¼0.001), and was also significantly increased in women who subsequently developed pregnancy-associated HTN vs those that did not (p<0.001) (Fig 2) . CONCLUSION: Sonographic evidence of NAFLD at 10-14 weeks is an independent risk factor for pregnancy-associated HTN. Circulating selenoprotein P levels are increased in patients with NAFLD, which may be linked to the development of pregnancy-associated HTN. OBJECTIVE: Adjuvant 17-hydroxyprogesterone caproate (17-OHPC) supplementation may improve health outcomes in women with a history of recurrent spontaneous preterm birth (SPTB) who received a history-indicated cerclage, but it is unclear whether 17-OHPC use is cost-effective in this setting. The aim of this study was to evaluate the cost-effectiveness of adjuvant 17-OHPC supplementation in preventing SPTB in women with a history-indicated (prophylactic cerclage). STUDY DESIGN: Baseline model parameters were sourced from randomized clinical trials and observational studies, and data was extracted for costs and outcomes of treatment. The primary outcome of interest is the number of preterm births averted by each strategy per 1,000 patients treated. Costs were discounted annually at 3%. Patients' outcomes were modeled for 80 years and incremental costeffectiveness ratios (ICER) were calculated from a payer perspective. The robustness of the results was performed by univariate and probabilistic sensitivity analyses by examining scatter plots of incremental costs and effectiveness. TreeAge Pro 2018 was used for data analysis. RESULTS: In the base case analysis, compared to prophylactic cerclage alone, adjuvant treatment with 17-OHPC was associated with lower incidence of preterm birth, and averted 40 more cases of SPTB per 1,000 patients treated, resulting in an incremental benefit of 3.26 QALYs and an ICER of 2,706 per QALY gained. Univariate sensitivity analysis showed findings to be robust under almost all scenarios. Probabilistic sensitivity analysis showed that there is a 58% probability that treatment with 17-OHPC was associated with a cost per QALY of less than $50,000. In 66% of Monte Carlo simulation of 10 million trials, adjuvant 17-OHPC was cost saving in comparison with prophylactic cerclage alone. CONCLUSION: This decision analysis demonstrates that adjuvant 17-OHPC was found to be cost effective and cost saving in treating women with a history of recurrent spontaneous preterm birth compared to prophylactic cerclage alone. The findings of the sensitivity analysis suggest that the results are robust to input variables.
